Market Overview:
The global brexanolone API market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of neurological disorders, increasing R&D investments by pharmaceutical companies and growing demand for novel therapeutics. However, the high cost of treatment and lack of awareness about neurological disorders are some factors that could hamper the growth of this market. The global brexanolone API market is segmented on the basis of type, application and region. On the basis of type, it is segmented into min purity less than 98%, min purity 98%-99% and min purity more than 99%. On the basis of application, it is segmented into research and pharmaceuticals. Geographically, it is divided into North America, Latin America, Europe Asia Pacific and Middle East & Africa.
Product Definition:
API stands for "Active Pharmaceutical Ingredient" and is the term used to describe the chemical compound(s) that are responsible for the drug's therapeutic effects. The Brexanolone API is a new, experimental drug being developed as a potential treatment for severe postpartum depression.
Min Purity Less Than 98%:
Brexanolone (R-ketamine) is an organic compound, which is a type of dissociative anesthesia. It's an analog of benzyl alcohol and was first developed by Dr. Robertet in France during the 1960s as an alternative to general anesthesia for surgical procedures. The drug has been approved by the U.
Min Purity 98%-99%:
Brexanolone (BnP98%-99%) is a chemical compound and an organic intermediate used in the production of chemicals, such as solvents, adhesives & sealants, detergents, surfactants and cosmetics. It is also used as a raw material for manufacturing other chemicals. Brexanolone finds application across various end-use industries including pharmaceuticals and healthcare; agriculture; oil & gas downstream processing industry; automotive lubricant additive market among others.
Application Insights:
Brexanolone API is used in the manufacturing of medicines for various applications including research and pharmaceutical. Research application dominated the overall market with a share of over 80% in 2017. This high share is attributable to growing R&D activities pertaining to new drug development for several chronic diseases such as cancer, diabetes, and cardiovascular diseases.
The pharmaceutical segment is expected to witness significant growth over the forecast period owing to increasing awareness regarding chronic diseases and their treatment globally coupled with rising health consciousness among people, especially in developed countries like U.S., Canada, France etc. Moreover, growing investments by governments for developing new healthcare facilities along with expanding retail network & product range by big pharma companies are further anticipated to boost market growth over the forecast period.
Regional Analysis:
North America was the largest market for brexanolone API and accounted for a revenue share of over 40.0% in 2017. The region is expected to maintain its dominance during the forecast period on account of increasing R&D activities, rising healthcare expenditure, and growing pharmaceutical industry in the U.S., Canada, and Mexico.
Growth Factors:
- Increasing prevalence of neurological disorders: The global prevalence of neurological disorders is increasing rapidly. This is mainly due to the aging population and the increase in lifestyle-related diseases. The Brexanolone API market is expected to benefit from this trend as it offers a potential treatment for these disorders.
- Growing demand for novel therapies: There is a growing demand for novel therapies that can offer better treatment outcomes than existing treatments options. The Brexanolone API market offers such a potential therapy and is expected to benefit from this trend.
- Rising investment in R&D: There is a significant amount of investment being made in R&D for new drugs, including those targeting neurological disorders. This will help drive the growth of the Brexanolone API market as more companies seek to commercialize products based on this therapy option.
Scope Of The Report
Report Attributes
Report Details
Report Title
Brexanolone API Market Research Report
By Type
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
By Application
Research, Pharmaceutical
By Companies
Teva Pharmaceutical Industries, Pharmaffiliates, Venkatasai Life Sciences, ACIC, PharmaZell Group, AlchemyPharm, Shaanxi Hanjiang Pharmaceutical, HUANHAO
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Brexanolone API Market Report Segments:
The global Brexanolone API market is segmented on the basis of:
Types
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research, Pharmaceutical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceutical Industries
- Pharmaffiliates
- Venkatasai Life Sciences
- ACIC
- PharmaZell Group
- AlchemyPharm
- Shaanxi Hanjiang Pharmaceutical
- HUANHAO
Highlights of The Brexanolone API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Min Purity Less Than 98%
- Min Purity 98%-99%
- Min Purity More Than 99%
- By Application:
- Research
- Pharmaceutical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Brexanolone API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Brexanolone API is a corticosteroid medication that is used to treat various conditions, including asthma, allergic rhinitis, and other types of allergies. Brexanolone API can also be used to reduce inflammation in the body.
Some of the major players in the brexanolone api market are Teva Pharmaceutical Industries, Pharmaffiliates, Venkatasai Life Sciences, ACIC, PharmaZell Group, AlchemyPharm, Shaanxi Hanjiang Pharmaceutical, HUANHAO.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Brexanolone API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Brexanolone API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Brexanolone API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Brexanolone API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Brexanolone API Market Size & Forecast, 2020-2028
4.5.1 Brexanolone API Market Size and Y-o-Y Growth
4.5.2 Brexanolone API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Min Purity Less Than 98%
5.2.2 Min Purity 98%-99%
5.2.3 Min Purity More Than 99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Research
6.2.2 Pharmaceutical
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Brexanolone API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Brexanolone API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Min Purity Less Than 98%
9.6.2 Min Purity 98%-99%
9.6.3 Min Purity More Than 99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Research
9.10.2 Pharmaceutical
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Min Purity Less Than 98%
10.6.2 Min Purity 98%-99%
10.6.3 Min Purity More Than 99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Research
10.10.2 Pharmaceutical
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Min Purity Less Than 98%
11.6.2 Min Purity 98%-99%
11.6.3 Min Purity More Than 99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Research
11.10.2 Pharmaceutical
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Min Purity Less Than 98%
12.6.2 Min Purity 98%-99%
12.6.3 Min Purity More Than 99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Research
12.10.2 Pharmaceutical
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Min Purity Less Than 98%
13.6.2 Min Purity 98%-99%
13.6.3 Min Purity More Than 99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Research
13.10.2 Pharmaceutical
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Brexanolone API Market: Competitive Dashboard
14.2 Global Brexanolone API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva Pharmaceutical Industries
14.3.2 Pharmaffiliates
14.3.3 Venkatasai Life Sciences
14.3.4 ACIC
14.3.5 PharmaZell Group
14.3.6 AlchemyPharm
14.3.7 Shaanxi Hanjiang Pharmaceutical
14.3.8 HUANHAO
